How It Works
Vitamin K2 is an enzymatic cofactor — it doesn't perform biological actions directly. Instead, it enables gamma-glutamyl carboxylase to activate other proteins by adding a carboxyl group to specific glutamic acid residues (a process called carboxylation). Two proteins depend on this activation:
Osteocalcin (bone): Inactive undercarboxylated osteocalcin (ucOC) cannot bind calcium. Once carboxylated by K2, it integrates circulating calcium into the hydroxyapatite mineral matrix of bone. K2 also drives osteoblast differentiation while suppressing osteoclast activity via the RANKL/NF-κB pathway — a dual mechanism for bone formation.
Matrix Gla Protein or MGP (arteries): Inactive dephosphorylated-uncarboxylated MGP (dp-ucMGP) is biologically inert and is itself a cardiovascular risk marker. Active MGP physically binds calcium crystals within arterial walls, preventing new soft-tissue calcification and preserving arterial elasticity. It doesn't dissolve existing plaque — it prevents new deposition.
Why form matters pharmacokinetically: MK-4 has a 1–3 hour half-life and clears rapidly, requiring 45mg/day in divided doses to maintain tissue levels. MK-7 binds to LDL and VLDL lipoproteins, extending its half-life to ~72 hours — a single 90–180mcg dose maintains round-the-clock carboxylation of both osteocalcin and MGP.
The Debate
Does K2 reduce fracture incidence?
Huang 2022 (before data cleaning)
K2 significantly reduces fracture incidence in postmenopausal women (RR 0.43, p=0.01)
VS
KDIGO 2025 / Mott 2019
K2 supplementation shows little to no significant fracture risk reduction in adults
Why they disagree: Early consensus was built on Japanese menatetrenone (MK-4) trials by Yoshihiro Sato — dozens retracted for data fabrication. Removing them collapses the fracture benefit in most independent analyses. The heterogeneity in the Huang 2022 meta-analysis almost entirely traces back to these retracted studies.
Does K2 improve vascular outcomes broadly?
AVADEC Trial (N=389, MK-7 720mcg + D3)
Significant slowing of CAC progression in elderly men with severe baseline calcification (CAC >400)
VS
Szczepańska 2023 meta-analysis (8 CKD studies)
No consistent effect on arterial stiffness or CAC scores across pooled CKD data
Why they disagree: K2's vascular benefit concentrates in active, rapidly-progressing calcification phenotypes (high CAC, diabetics, hemodialysis). In populations where existing plaques are established and mostly static, K2 doesn't show consistent benefit. The disease stage matters as much as the supplement.
Does K2 benefit non-diabetic CKD patients?
Naiyarakseree 2023 (MK-7, diabetic HD patients)
Significant reduction in arterial stiffness (cfPWV −10%, p=0.008) in the diabetic subgroup
VS
Valkyrie Trial 2020 (non-diabetic HD patients)
No improvement in pulse wave velocity or vascular calcification markers
Why they disagree: K2's activation of osteocalcin improves insulin sensitivity and pancreatic beta-cell function — a secondary mechanism that benefits arterial elasticity specifically in T2D patients. Non-diabetic patients don't receive this additional pathway.
Honest Limitations
Lab vs Reality: Absorption compliance
Lab: Studies carefully control fat co-ingestion. Reality: Most consumers take supplements first thing in the morning with water — zero fat, zero bile stimulation, minimal K2 absorption. MK-7 taken fasted is largely wasted. Direction: more conservative than lab suggests.
Lab vs Reality: Retracted data contamination
Lab: The K2 literature has now formally retracted dozens of Japanese MK-4 trials (Yoshihiro Sato, Jun Iwamoto). Reality: Most blog content, practitioner recommendations, and supplement marketing still cite these studies. Consumer expectations are inflated beyond the corrected evidence base. Direction: fracture evidence much weaker than commonly stated.
Lab vs Reality: Surrogate markers vs hard endpoints
Lab: ucOC and dp-ucMGP reliably decrease within 12–24 weeks of MK-7 supplementation. Reality: Whether those biomarker improvements prevent a hip fracture or heart attack over 10 years requires long-term outcome data that current 1–3 year RCTs can't provide. Direction: consumer expectations of definitive protection should be tempered.
The Nuance
' width='800' height='400'/%3E%3C/svg%3E)
The Statin Interaction — Why It Matters
Statins inhibit HMG-CoA reductase, blocking a pathway that the body also uses to synthesise endogenous K2. Long-term statin therapy effectively depletes the K2 needed to carboxylate MGP — the protein that prevents arterial calcification. This creates an ironic situation: statins prescribed to reduce cardiovascular risk may simultaneously deplete the nutrient that protects arterial walls from calcification. K2 supplementation restores MGP carboxylation capacity. The mechanistic case is compelling; large independent outcome RCTs specifically in statin-treated populations are still needed.
What "Calcium Routing" Actually Means
The calcium routing mechanism is well-established biochemically — reductions in dp-ucMGP and ucOC are universally replicated in humans. But translating "activated MGP" to "actually preventing arterial plaques" requires decades of follow-up that short RCTs can't capture. The mechanism is real; the clinical magnitude for the general population is still being quantified.
What DOESN'T Work
- K2 reverses existing arterial plaques: No evidence. It slows new calcification in high-risk cohorts — established hardened plaque is not affected.
- K2 alone prevents fractures (without D3/calcium/bisphosphonates): The fracture evidence was largely built on retracted trials. Modern independent data doesn't support monotherapy fracture prevention.
- Any K2 dose is safe for warfarin users: False. Even 10mcg MK-7 — a fraction of one capsule — causes clinically relevant INR lowering. There is no safe dose of K2 for VKA users without specialist supervision.
- MK-4 at supplement doses (45–200mcg) works like MK-7: MK-4 clears in 1–3 hours. Low-dose MK-4 is essentially inactive at the tissue level. The 45mg Japanese protocols require 3× daily dosing for a reason.
Cost-Effectiveness
| Protocol | Monthly Cost (approx) | Food Alternative |
|---|
| MK-7 90–180mcg (general) | £8–15/month | ~1 tablespoon natto/day — not realistic for most Western diets |
| MK-7 360–375mcg (high-risk: CKD/CAC) | £15–25/month | No realistic food equivalent |
